Alliance Pharma PLC Completion of acquisition of Vamousse (3992A)
December 28 2017 - 2:00AM
UK Regulatory
TIDMAPH
RNS Number : 3992A
Alliance Pharma PLC
28 December 2017
For immediate release 28 December 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Completion of acquisition of Vamousse(R)
On 4 December 2017 Alliance Pharma plc (AIM: APH), the specialty
pharmaceutical company, announced that its wholly owned subsidiary,
Alliance Pharmaceuticals Limited, had entered into an agreement to
acquire the worldwide rights to Vamousse from TyraTech Inc (AIM:
TYR and TYRU) (the "Acquisition").
Further to Tyratech's announcement on 27 December 2017 that its
shareholders have approved the Acquisition, Alliance is pleased to
announce that it has today completed the Acquisition.
Alliance is also pleased to announce the appointment of Amanda
Sicvol as Country Manager for its newly created US affiliate.
Amanda has been instrumental in the commercial success of Vamousse
to date, having worked for Tyratech for four years. She brings
significant expertise and considerable knowledge of the Vamousse
brand.
John Dawson, Alliance Pharma's Chief Executive Officer,
commented: "The completion of this acquisition provides Alliance a
third International star brand with best in class technology. There
is also real potential for further growth through our substantial
global network of distributors. We are delighted to welcome Amanda
to Alliance to establish our presence in the US, the largest
consumer healthcare market in the world."
- Ends -
For further information:
+ 44 (0) 1249
Alliance Pharma plc 466966
John Dawson, Chief Executive
Officer
Peter Butterfield, Deputy Chief
Executive Officer
Andrew Franklin, Chief Financial
Officer
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Wills /
Gemma Mostyn-Owen
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James Black
/ Toby Adcock
+44 (0) 20 7597
Investec Bank plc 5970
Corporate Finance: Daniel Adams
/ Ed Thomas
Corporate Broking: Patrick
Robb / Rob Baker
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Group has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Group continues to explore opportunities to expand its product
portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ACQDDBDDRUDBGRR
(END) Dow Jones Newswires
December 28, 2017 02:00 ET (07:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024